China Resources Pharma reveals key subsidiary financials

Hong Kong-listed China Resources Pharmaceutical Group (HKEX: 3320) today announced the 2024 financial results of its key subsidiaries, CR Double-Crane and Jiangzhong Pharmaceutical. CR Double-Crane reported a decrease in total assets by 8.33% to RMB 16.69 billion and a 14.78% drop in net assets attributable to shareholders, settling at RMB 10.41 billion. Revenue dipped slightly by 0.87% to RMB 11.21 billion, while net profit attributable to shareholders experienced a 2.55% decrease. The company is proposing a cash dividend of RMB 3.71 per 10 shares.